HYDROXYCHLOROQUINE SULFATE

Manufacturer
DIRECT RX
Effective date
2016-10-27
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
legacy-cache
Hydrated at
2026-08-02 01:22:05

Label at a glance#

ProductHYDROXYCHLOROQUINE SULFATE
Active ingredientHYDROXYCHLOROQUINE SULFATE
Label structure10 sections

Boxed warning

WARNING PHYSICIANS SHOULD COMPLETELY FAMILIARIZE THEMSELVES WITH THE COMPLETE CONTENTS OF THIS LEAFLET BEFORE PRESCRIBING HYDROXYCHLOROQUINE.

Label contents#

Full prescribing information#

BOXED WARNING SECTION

WARNING

PHYSICIANS SHOULD COMPLETELY FAMILIARIZE THEMSELVES WITH THE COMPLETE CONTENTS OF THIS LEAFLET BEFORE PRESCRIBING HYDROXYCHLOROQUINE.

DESCRIPTION SECTION

Hydroxychloroquine sulfate is an odorless, white or practically white crystalline powder, freely soluble in water; practically insoluble in alcohol, in chloroform, and in ether. Chemically the drug is 2-[[4-[(7-Chloro-4-quinolyl) amino] pentyl] ethylamino] ethanol sulfate (1:1).

Each hydroxychloroquine sulfate tablet intended for oral administration contains 200 mg of hydroxychloroquine sulfate equivalent to 155 mg base. In addition, each tablet contains the following inactive ingredients: dibasic calcium phosphate dihydrate, magnesium stearate, pregelatinized starch, polyethylene glycol, polyvinyl alcohol, starch, talc and titanium dioxide.

CLINICAL PHARMACOLOGY SECTION

The drug possesses antimalarial actions and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. The precise mechanism of action is not known.

INDICATIONS & USAGE SECTION

Hydroxychloroquine sulfate tablets are indicated for the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.

CONTRAINDICATIONS SECTION

Use of this drug is contraindicated (1) in the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound, (2) in patients with known hypersensitivity to 4-aminoquinoline compounds, and (3) for long-term therapy in children

WARNINGS SECTION

General

Hydroxychloroquine sulfate tablets are not effective against chloroquine-resistant strains of P. falciparum.

Children are especially sensitive to the 4-aminoquinoline compounds. A number of fatalities have been reported following the accidental ingestion of chloroquine, sometimes in relatively small doses (0.75 g or 1 g in one 3-year-old child). Patients should be strongly warned to keep these drugs out of the reach of children.

Use of hydroxychloroquine sulfate tablets in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria the condition may be exacerbated. The preparation should not be used in these conditions unless in the judgment of the physician the benefit to the patient outweighs the possible hazard.

Usage in Pregnancy

Usage of this drug during pregnancy should be avoided except in the suppression or treatment of malaria when in the judgment of the physician the benefit outweighs the possible hazard. It should be noted that radioactively-tagged chloroquine administered intravenously to pregnant, pigmented CBA mice passed rapidly across the placenta. It accumulated selectively in the melanin structures of the fetal eyes and was retained in the ocular tissues for five months after the drug had been eliminated from the rest of the body.

PRECAUTIONS SECTION

General

Antimalarial compounds should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.

Periodic blood cell counts should be made if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuation of the drug should be considered. The drug should be administered with caution in patients having G-6-PD (glucose-6-phosphate dehydrogenase) deficiency.

OVERDOSAGE SECTION

The 4-aminoquinoline compounds are very rapidly and completely absorbed after ingestion, and in accidental overdosage, or rarely with lower doses in hypersensitive patients, toxic symptoms may occur within 30 minutes. These consist of headache, drowsiness, visual disturbances, cardiovascular collapse, and convulsions, followed by sudden and early respiratory and cardiac arrest. The electrocardiogram may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, and progressive bradycardia leading to ventricular fibrillation and/or arrest. Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by emesis (at home, before transportation to the hospital) or gastric lavage until the stomach is completely emptied. If finely powdered, activated charcoal is introduced by the stomach tube, after lavage, and within 30 minutes after ingestion of the tablets, it may inhibit further intestinal absorption of the drug. To be effective, the dose of activated charcoal should be at least five times the estimated dose of hydroxychloroquine ingested. Convulsions, if present, should be controlled before attempting gastric lavage. If due to cerebral stimulation, cautious administration of an ultrashort-acting barbiturate may be tried but, if due to anoxia, it should be corrected by oxygen administration, artificial respiration or, in shock with hypotension, by vasopressor therapy. Because of the importance of supporting respiration, tracheal intubation or tracheostomy, followed by gastric lavage, may also be necessary. Exchange transfusions have been used to reduce the level of 4-aminoquinoline drug in the blood.

A patient who survives the acute phase and is asymptomatic should be closely observed for at least six hours. Fluids may be forced, and sufficient ammonium chloride (8 g daily in divided doses for adults) may be administered for a few days to acidify the urine to help promote urinary excretion in cases of both overdosage and sensitivity.

HOW SUPPLIED SECTION

Hydroxychloroquine Sulfate Tablets, USP contain 200 mg of hydroxychloroquine sulfate, equivalent to 155 mg base, are white to off-white, capsule-shaped, biconvex, film-coated tablets debossed with "ZC38" on one side and plain on other side, and are supplied as follows:

NDC 68382-096-01 in bottles of 100 tablets                      

NDC 68382-096-05 in bottles of 500 tablets

NDC 68382-096-30 in unit-dose blister cartons of 100 (10 x 10) unit dose tablets

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP/NF.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

132132

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeData Matrix61919-132-30 AHG4O 12/17132-30.jpg

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
61919-132-30EA - Each61919-1321a805822-41a5-4d92-b4a9-6452ea0a7f2112015-04-03
68382-096-01EA - Each68382-0961ad94c26-4b39-4410-9089-964e237ae87212012-07-24
68382-096-05EA - Each68382-096dd0cb769-0b6a-4de0-a1f3-d794b00a31a512012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
HYDROXYCHLOROQUINE SULFATEACTIVE INGREDIENT8Q2869CNVH2
HYDROXYCHLOROQUINEACTIVE MOIETY4QWG6N8QKH2
DIBASIC CALCIUM PHOSPHATE DIHYDRATEINACTIVE INGREDIENTO7TSZ97GEP2
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I302
POLYETHYLENE GLYCOLSINACTIVE INGREDIENT3WJQ0SDW1A2
POLYVINYL ALCOHOLINACTIVE INGREDIENT532B59J9902
STARCH, CORNINACTIVE INGREDIENTO8232NY3SJ2
TALCINACTIVE INGREDIENT7SEV7J4R1U2
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JP2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
61919-13261919-132-30
68382-096

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 6 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, FILM COATED / ORAL96 mgExact identifier — unii+route+dosage form
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPTABLET, FILM COATED / ORAL36 mgExact identifier — unii+route+dosage form
DIBASIC CALCIUM PHOSPHATE DIHYDRATEDIBASIC CALCIUM PHOSPHATE DIHYDRATEO7TSZ97GEPTABLET, FILM COATED / ORAL953 mgExact identifier — unii+route+dosage form
POLYVINYL ALCOHOLPOLYVINYL ALCOHOL532B59J990TABLET, FILM COATED / ORAL20 mgExact identifier — unii+route+dosage form
TALCTALC7SEV7J4R1UTABLET, FILM COATED / ORAL91 mgExact identifier — unii+route+dosage form
STARCH, CORNSTARCH, CORNO8232NY3SJTABLET, FILM COATED / ORAL2000 mgExact identifier — unii+route+dosage form

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A040657-001HYDROXYCHLOROQUINE SULFATEHYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A040657-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21d4dbc9d85df4…
2026-10-15 13:18:302026-09A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21c2088c7a36db…
2026-09-14 22:38:342026-08A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-2184e616aacf4f…
2026-08-18 06:07:402026-07A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-2131067a03dcf5…
2025-08-23 18:47 UTC2025-08A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-216a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-2103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-212680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-215bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-2179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-211e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-218072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-215c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-215d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-214b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-2174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-2187673890dc5c…
2021-03-12 10:30 UTC2021-03A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-215aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-218869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-213f01610625f2…
2019-09-15 20:21 UTC2019-09A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21b00525d2431f…
2019-07-19 19:46 UTC2019-07A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-216a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-211c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-219b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-213f0d92c62455…
2023-05-13 08:27 UTC2023-05A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-21053a50430f4f…
2023-01-26 05:58 UTC2023-01A040657-001HYDROXYCHLOROQUINE SULFATE200MGTABLET / ORALAB2007-09-213bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A040657-001AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A040657-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A040657-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A040657-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A040657-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A040657-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A040657-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A040657-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A040657-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A040657-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A040657-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A040657-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A040657-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A040657-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A040657-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A040657-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A040657-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A040657-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A040657-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A040657-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A040657-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A040657-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A040657-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A040657-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A040657-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A040657-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A040657-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A040657-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A040657-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A040657-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A040657-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A040657-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A040657-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A040657-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A040657-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A040657-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A040657-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A040657-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A040657-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A040657-001AB13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Hydroxychloroquine sulfateHYDROXYCHLOROQUINE SULFATEZydus Pharmaceuticals USA Inc.805a1acd-2e0d-48f1-af6b-0e5d8e06c2282023-12-19Warnings, Adverse reactionsExact identifier
ndc (product): 68382-096
3fda9074-20e6-639c-e054-00144ff88e8888bd448d-bac7-4839-816a-8b800d7705c42016-10-27Boxed warning, WarningsExact identifier
spl id: 3fda9074-20e6-639c-e054-00144ff88e88
spl set id: 88bd448d-bac7-4839-816a-8b800d7705c4

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.